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Abstract
Dapagliflozin, a new type of drug used to treat diabetes mellitus (DM), is a sodium/glucose
cotransporter 2 (SGLT2) inhibitor. Although some studies showed that SGLT2 inhibition
attenuated reactive oxygen generation in diabetic kidney the role of SGLT2 inhibition is
unknown. We evaluated whether SLT2 inhibition has renoprotective effects in ischemia-
reperfusion (IR) models. We evaluated whether dapagliflozin reduces renal damage in IR
mice model. In addition, hypoxic HK2 cells were treated with or without SGLT2 inhibitor to
investigate cell survival, the apoptosis signal pathway, and the induction of hypoxia-induc-
ible factor 1 (HIF1) and associated proteins. Dapagliflozin improved renal function. Dapagli-
flozin reduced renal expression of Bax, renal tubule injury and TUNEL-positive cells and
increased renal expression of HIF1 in IR-injured mice. HIF1 inhibition by albendazole
negated the renoprotective effects of dapagliflozin treatment in IR-injured mice. In vitro,
dapagliflozin increased the expression of HIF1, AMP-activated protein kinase (AMPK), and
ERK and increased cell survival of hypoxic HK2 cells in a dose-dependent manner. In con-
clusion, dapagliflozin attenuates renal IR injury. HIF1 induction by dapagliflozin may play a
role in renoprotection against renal IR injury.
Introduction
Although there are numerous causes of AKI including ureteral obstruction, calcineurin inhibi-
tor toxicity and kidney ischemia, renal ischemic-reperfusion (IR)-induced injury is a major
cause of AKI in patients undergoing renal transplantation [1–3]. Complex mechanisms are
involved in IR injury, including hypoxic injury, tubular cell secretion of cytokines associated
with apoptotic cell death, and acute inflammatory processes [4, 5]. Moreover, reperfusion fol-
lowing by ischemia generates massive quantities of reactive oxygen species (ROS), which
result in tubular cell death [5]. However, ischemic tubule cells activate an adaptive process for
PLOSONE | DOI:10.1371/journal.pone.0158810 July 8, 2016 1 / 14
a11111
OPEN ACCESS
Citation: Chang Y-K, Choi H, Jeong JY, Na K-R, Lee
KW, Lim BJ, et al. (2016) Dapagliflozin, SGLT2
Inhibitor, Attenuates Renal Ischemia-Reperfusion
Injury. PLoS ONE 11(7): e0158810. doi:10.1371/
journal.pone.0158810
Editor: David Long, UCL Institute of Child Health,
UNITED KINGDOM
Received: January 25, 2016
Accepted: June 22, 2016
Published: July 8, 2016
Copyright: © 2016 Chang et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by a Clinical
Research Institute grant (CMCDJ-A-2015–020)
funded by The Catholic University of Korea Daejeon
St. Mary’s Hospital. This study was supported by a
faculty research grant of Yonsei University College of
Medicine for 2009 (6-2009-0103). The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
survival against hypoxia. Hypoxia-inducible factor 1 (HIF1) is a key protein that regulates such
adaptive cellular or tissue responses to hypoxia [6]. HIF1 has an oxygen-sensitive α subunit
and a constitutively expressed β subunit [7]. Transcriptional regulation of HIF1 occurs when
the HIF1 heterodimer binds to hypoxia response elements [7].
HIF1 functions as a protective molecule in hypoxic organs including the brain, heart, liver
and kidney [8–11]. HIF1 induction by ischemic preconditioning reduced renal apoptosis
and inflammation in IR injury [12]. In addition, stabilization of HIF1 by inhibition of prolyl
hydroxylase domain (PHD) attenuated ischemic kidney injury [13].
Besides hypoxia, several other mediators can regulate HIF1, such as reactive oxygen species
(ROS), cobalt chloride, nitric oxide, tumor necrosis factor-α, and angiotensin II [7]. HIF1 is
involved in the regulation of many biological processes related to kidney function, including
glucose and energy metabolism, angiogenesis, erythropoiesis, iron homeostasis, cell migration,
vasomotor regulation, and cell–cell/cell–matrix interactions [7]. HIF1 induction reduces
SGLT2 levels in kidney tubule cells; however, it is unclear whether SLGT2 inhibition regulates
HIF1 [14].
Dapagliflozin, a new pharmacological therapy for type 2 diabetes, inhibits sodium/glucose
cotransporter 2 (SGLT2), which results in excretion of glucose into the urine. SGLT2 inhibition
reduced hyperfiltration, tubular oxidative stress, and oxygen consumption in a diabetic kidney
[15–17]. However, SGLT2 inhibition also showed mild increase of oxygen consumption, which
may induce renal hypoxia in non-diabetic rat kidney [16]. In this study, we evaluated whether
dapagliflozin has a renoprotective effect in renal IR-injured mice and investigated the mecha-
nism involved, including HIF1 regulation.
Materials and Methods
Mice and drugs
All of the experiments were performed using 10-week-old male C57BL/6 mice weighing 30–33
g each (Damul Science, Daejeon, Korea). The mice were given a standard laboratory diet
(Damul Science, Daejeon, Korea) and water, and were cared for according to a protocol
approved by the Institutional Animal Care and Use Committee of the Catholic University
Medical School (CMCDJ-2014-001). The mice were divided into five groups: vehicle (Vh)-
treated sham (n = 5), dapagliflozin-treated sham (n = 5), Vh-treated IR (n = 7), dapagliflozin-
treated IR (n = 7), and albendazole and dapagliflozin treated IR (n = 7). Dapagliflozin (Astraze-
neca Co., NJ, USA) was administrated via oral gavage at a dose of 10 mg/kg/day for 2 days,
starting 24 h before surgery. Albendazole was injected subcutaneously 1 h before IR surgery.
IR injury was performed as described previously [5]. Briefly, mice were anesthetized with an
intraperitoneal injection of ketamine (60 mg/kg body mass) and xylazine (8 mg/kg). After an
abdominal incision, both renal pedicles were bluntly clamped. During the procedure, the
mouse’s body temperature was kept constant at 35–36°C on a heating pad. The clamps were
removed after 27 min of ischemia. Sham-treated control mice underwent a similar surgical pro-
cedure without clamping. Mice were sacrificed at 24 h after the surgical procedure, and the
blood and kidneys were collected.
Blood and tissue preparation
Blood was collected from the inferior vena cava at sacrifice under anesthesia. The blood was
placed into pre-chilled Eppendorf tubes (4°C). Serum was separated by centrifugation for 10
min at 4°C. Aliquots of serum were shock-frozen using liquid nitrogen and stored at −70°C.
Tissues were prepared as described previously [18]. Briefly, the left kidney was excised immedi-
ately after sacrifice and cut into three coronal sections. Two pieces of the kidney were snap-
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frozen in liquid nitrogen and kept at −70°C for subsequent RNA extraction and protein analy-
sis. The other kidney portion was fixed in 10% buffered formaldehyde at room temperature
and then embedded in paraplast (Sherwood Medical, St. Louis, MO, USA) for light microscopy
and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analyses.
Cell culture and drug treatment
HK-2, an immortalized proximal tubule epithelial cell line, was purchased from the American
Type Culture Collection (Manassas, VA, USA) and cultured. Briefly, cells were passaged every
3–4 days in 100-mm dishes (Falcon, Bedford, MA, USA) using Dulbecco’s modified Eagle’s
medium-F12 (Sigma-Aldrich, St. Luis, MO, USA) supplemented with 10% fetal bovine serum
(Life Technologies Inc., Gaithersburg, MD, USA), insulin-transferrin-sodium selenite media
supplement (Sigma-Aldrich), 100 U/ml penicillin, and 100 mg/mL streptomycin (Sigma-
Aldrich). For experimental use, these cells were incubated in a humidified atmosphere of 5%
CO2, 95% air at 37°C for 24 h and subcultured at 70–80% confluence.
Hypoxia was simulated by immersing HK-2 cell monolayers in mineral oil (Sigma-Aldrich)
for 30 min at 37°C. After washing extensively with PBS, the cells were incubated in DMEM/
F12 medium supplemented with 10% FBS for 24 h after medium replacement. These cells were
pretreated with various doses of dapagliflozin for 2hr. The cell were harvested at the end of
hypoxia for molecular analysis including HIF-1, AMPK, and EKR. For glucose assay, glucose
in the medium was measured with glucose assay kit (Abcam ab65333), according to the manu-
facturer’s instructions. Glucose consumptions in each groups (control: normoxia and non-
treated, Dapa1: normoxia and dapagliflozin 1μM treated, Dapa10: normoxia and dapagliflozin
10μM treated, Hypoxia: hypoxia with non-treated, Hypoxia Dapa1: hypoxia with dapagliflozin
1μM treated, Hypoxia Dapa10: hypoxia with dapagliflozin 10μM treated) were calculated,
comparing to control group. All cellular experiment repeated three times for western blot and
glucose assay.
Cell viability assay
To perform the cell survival assay, cells were collected after 24 h incubation with vehicle or
dapagliflozin pretreatment in 30-min ischemia and surviving cells were counted with Trypan
blue staining. The percentage survival was determined by quantization of the relative viable
number of treated cells divided by the viable number of untreated cells.
Western blot
Western blot was performed for protein analysis as described previously [4]. Briefly, kidney
sections were homogenized in protein extraction solution (PRO-PREP, iNtRON, Sungnam-si,
Korea); 40 μg of total protein were loaded in a stacking polyacrylamide gel and resolved on an
8 and 15% polyacrylamide gel with a biotinylated molecular weight standard marker. Then, the
samples were wet-transferred to a 0.2-μm nitrocellulose membrane (Amersham Pharmacia
biotech, NY, USA). The blots were blocked for 1 h with 5% non-fat dry milk in TBST buffer
(20 mM Tris–HCl [pH 7.6], 0.8% NaCl and 0.05% Tween 20) and incubated overnight at 4°C
with a 1:1000 anti-HIF-1-alpha antibody (HIF-1; Abcam, Cambridge, MA, USA), AMP-acti-
vated protein kinase (AMPK; Cell Signaling Technology, Inc., Beverly, MA, USA), anti-Bax
antibody (Cell Signaling Technology, Inc.), anti-Bcl2 antibody (Cell Signaling Technology,
Inc.), and poly ADP ribose polymerase (PARP, Cell Signaling Technology, Inc.). The blots
were incubated with 1:1000 secondary anti-rabbit IgG-HRP-linked antibody or 1:1000 second-
ary anti-goat IgG- HRP-linked antibody (Cell Signaling Technology, Inc.) for 1 h. The bands
were detected using enhanced chemiluminescence (Millipore, Billerica, MA, USA), and
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exposed to films. The optical density for quantification was obtained using Gel-Pro Analyzer
version 3.1 (Media Cybernetics, Silver Spring, MD, USA).
Tubular injury score
Paraffin-embedded kidney pieces were cut into 4-μm sections and mounted on glass slides.
The sections were deparaffinized with xylene, stained with hematoxylin and eosin (H&E) and
periodic acid-Schiff (PAS), and examined under an Olympus BX51 microscope (Olympus,
Tokyo, Japan). In the H&E sections, renal cortical vacuolization, peritubular/proximal tubule
leukocyte infiltration, and proximal tubule simplification were evaluated and scored as follows:
0, normal; 1, mild injury; 2, moderate injury; 3, severe injury. Tubular damage (epithelial
necrosis) in PAS-stained sections was scored as follows: 0, normal; 1,<10%; 2, 10–25%; 3, 26–
75%; 4,>75%. Tubular necrosis was defined as the loss of proximal tubular brush border bleb-
bing of apical membranes, or intraluminal aggregation of cells and proteins, as described previ-
ously [4]. Kidney sections were evaluated by an experienced pathologist in a blind fashion. At
least 5 fields (magnification, ×200) were reviewed for each slide (n = 5, each groups).
TUNEL assay
TUNEL was performed using the in situ Apoptosis Detection Kit (S7100-KIT; EMDmilipore,
CA, USA) as described previously [19]. Briefly, the 4-μm-thick paraffin embedded sections
were dewaxed. The sections were incubated in 0.3% H2O2 at room temperature to eliminate
the endogenous peroxidase activity. Proteinase K (10 μg/mL in 0.1-M Tris, 50-mM EDTA [pH
8]) was applied to the sections for 15 min at room temperature. TdT enzyme was applied to the
sections and incubated in a humidified chamber for 1 h at 37°C to allow extension of the nicked
ends of the DNA fragments with digoxigenin-dUTP. Color was developed using 0.05% DAB
with 0.006% H2O2 as substrate. For negative controls, distilled water was used instead of TdT
enzyme.
Immunohistochemistry
Immunohistochemistry was performed as described previously [17]. Paraffin wax-embedded
tissues were cut into 4 μm sections, mounted on glass slides, and stained using indirect immu-
noperoxidase. The slides were processed for identification of HIF-1-alpha expression (anti-
HIF-1-alpha; Abcam, Cambridge, MA, USA), followed by detection using diaminobenzidine
(Sigma Chemical Co., St. Louis, MO, USA). All of the samples were evaluated under an Olym-
pus BX51 microscope. The the areas stained for HIF1-alpha, as percentages of the total area in
10 different fields of each section under 200× magnification, were determined automatically
using a digital camera-based image analyzer (Metamorpho, ver. 4.6).
Statistical analysis
Data are reported as means ± standard deviation (SD). Multiple comparisons among groups
were performed using one-way analysis of variance (ANOVA) with a post-hoc Bonferroni test
correction (SPSS 11.0 for Windows; SPSS, Inc., Chicago, IL, USA). P values< 0.05 were con-
sidered to indicate statistical significance.
Results
The effects of dapagliflozin on renal function and histology
The levels of BUN and serum creatinine in mice were significantly elevated 24 h after IR injury.
Dapagliflozin reduced the level of BUN and serum creatinine in IR-injured mice (Fig 1). In
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histologic evaluation, IR-injured kidneys showed loss of brush border, vacuolization, and des-
quamation of epithelial cells in renal tubular epithelium. Pretreatment with dapagliflozin atten-
uated the renal tubular injuries (Fig 2).
Anti-apoptotic effect of dapagliflozin
In vitro, dapagliflozin pretreatment showed no effect on the cell survival of normoxic HK2
cells. Hypoxia significantly decreased the cell viability of HK2 cells compared with control
cells, and dapagliflozin pretreatment of hypoxic HK2 cells significantly improved the cell via-
bility in a dose-dependent manner (Fig 3A). Bax expression was elevated significantly in hyp-
oxic HK2 cells, whereas dapagliflozin pretreatment decreased Bax expression in hypoxic
HK2 cells. The Bax/Bcl-2 ratio, used as an index of apoptotic signaling, showed a significant
increase in hypoxic HK2 cells, whereas dapagliflozin pretreatment decreased the Bax/Bcl2
ratio (Fig 3B). Also, dapagliflozin pretreatment decreased PARP expression in hypoxic HK2
cells.
In vivo, Bax expression was increased significantly and Bcl2 expression was decreased in IR-
injured kidneys compared with the expression levels in sham-treated mice. However, dapagli-
flozin pretreatment decreased Bax expression and increased Bcl2 expression in IR-injured kid-
neys. In addition, dapagliflozin pretreatment decreased PARP expression in IR injured kidneys
(Fig 4A). The TUNEL assay showed a significant increase in TUNEL-positive cells in IR-
injured kidneys; however, dapagliflozin pretreatment significantly reduced the number of
TUNEL-positive cells in IR-injured kidneys (Fig 4B).
Fig 1. Effects of dapagliflozin on renal function (S(n = 5), sham; S + Dapa (n = 5), sham + dapagliflozin; IR(n = 7), vehicle-treated renal IR mice;
IR + Dapa (n = 7), dapagliflozin-treated IRmice). Dapagliflozin pretreatment reduced BUN and serum creatinine in IR-injured mice. *P < 0.05 vs.
vehicle-treated sham, #P < 0.05 vs. vehicle-treated IR. Bar represents mean ± s.d.(Standard deviation).
doi:10.1371/journal.pone.0158810.g001
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Fig 2. Representative kidney section stained for hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS). (S(n = 5); S + Dapa (n = 5), IR
(n = 7), IR + Dapa (n = 7)). (A) H&E stain, yellow arrows indicate cell debri and tubular necrosis. Yellow arrowheads indicate inflammatory cells.
Original magnification, 200×. (B) Semi-quantitative analysis of tubule interstitial injury in wild-type and dapagliflozin- and/or albendazole-treated mice
24 h after renal IR injury (C) PAS stain. Yellow arrows indicate necrotized tubules or cast formation. Yellow arrowheads indicate loss of brush border
or dilated tubules. Black arrow indicates brush border. Original magnification, 200×. (D) Semi-quantitative analysis of tubular injury in wild-type and
dapagliflozin- and/or albendazole-treated mice 24 h after renal IR injury. *P < 0.05 vs. vehicle-treated sham, #P < 0.05 vs. vehicle-treated IR. Bar
represents mean ± s.d.
doi:10.1371/journal.pone.0158810.g002
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Fig 3. Effects of dapagliflozin on HK2 cell survival and apoptosis. (A) Dapagliflozin significantly
increased the cell survival in hypoxic HK2 cell in a dose-dependent manner. (B) Representative western blot
(B-a). Dapagliflozin significantly decreased the Bax expression and Bax/Bcl2 ratio in hypoxic HK2 cells (B-b
and d). However, Bcl2 expression was unaffected by dapagliflozin in hypoxic HK2 cells (B-c). Dapagliflozin
significantly decreased the PARP expression in hypoxic HK2 cells (B-e) *P < 0.05 vs. normoxic HK2 cells,
Dapagliflozin Attenuates Renal Injury
PLOS ONE | DOI:10.1371/journal.pone.0158810 July 8, 2016 7 / 14
#P < 0.05 vs. control hypoxic HK2 cells. Bar represents mean ± s.d. All cellular experiment repeated three
times for cell viability test and western blot.
doi:10.1371/journal.pone.0158810.g003
Fig 4. Effects of dapagliflozin on apoptosis in IR-injured kidneys (S(n = 5); S + Dapa (n = 5), IR(n = 7), IR + Dapa (n = 7)). (A) Western
blot analysis shows dapagliflozin decreased Bax expression and increased Bcl2 expression in IR-injured kidneys. Dapalgliflozin decreased
PARP expression in IR-injured kidneys. (B) Representative kidney section. Dapagliflozin decreased the TUNEL-positive cells in an IR-injured
kidney. *P < 0.05 vs. sham kidney, #P < 0.05 vs. IR kidney. Bar represents mean ± s.d.
doi:10.1371/journal.pone.0158810.g004
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The effects of SGLT2 on HIF1
Hypoxic HK2 cells showed marked elevation in HIF1 expression compared with that in control
HK2 cells. Dapagliflozin pretreatment further increased the HIF1 expression in hypoxic HK2
cells. Additionally, dapagliflozin increased AMPK and EKR phosphorylation in hypoxic HK2
cells. Although a high dose of dapagliflozin elevated HIF1 expression, it showed no effect on
the phosphorylation of AMPK and ERK in normoxic HK2 cells (Fig 5A). Hypoxia significantly
Fig 5. Effects of dapagliflozin on HIF1 in HK2 cells. (A) Representative Western blot: dapagliflozin increased HIF1 expression and
phosphorylation of AMPK and ERK in hypoxic HK2 cells. *P < 0.05 vs., dapagliflozin nontreated normoxic HK2 cells, #P < 0.05 vs. normoxic HK2
cells. **P < 0.05 vs. control hypoxic HK2 cells. (B) Representative Western blot: hypoxia increased HIF1 expression and decreased SGTL2
expression. Dapagliflozin pretreatment decrease SGLT2 expression in hypoxic HK2 cells. *P < 0.05 vs., dapagliflozin nontreated normoxic HK2
cells, #P < 0.05 vs. normoxic HK2 cells. **P < 0.05 vs. control hypoxic HK2 cells. (C) Dapaglilfozin pretreatment increase HIF1 expression in
normoxic and hypoxic HK2 cells compared to control and hypoxic control HK2 cells respectively. Albendazole decreased HIF1 expression in
dapagliflozin-treated hypoxic HK2 cells. *P < 0.05 vs., control HK2 cells, #P < 0.05 vs.control hypoxic HK2 cells. **P < 0.05 vs. albendazole
nontreated—dapagliflozin treated hypoxic HK2 cells. (D) Albendazole decreased cell survival in dapagliflozin-treated hypoxic HK2 cells. *P < 0.05
vs., control hypoxic HK2 cells #P < 0.05 vs.dapagliflozin treated hypoxic HK2 cells. (E) Dapagliflozin decreased glucose uptake in hypoxic HK2
cells. *P < 0.05 vs., hypoxic HK2 cells. Bar represents mean ± s.d. All cellular experiment repeated three times for western blot, cell viability
test, and glucose uptake test.
doi:10.1371/journal.pone.0158810.g005
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decreased the SGLT2 expression in HK2 cells. Dapagliflozin pretreatment significantly elevated
HIF1 expression and decreased SGLT2 expression (Fig 5B). HIF1 inhibitor, albendazole pre-
treatment significantly reduced the dapagliflozin-induced HIF elevation (Fig 5C). In addition,
albendazole pretreatment reduced the dapagliflozin-induced cell viability improvement (Fig
5D). 10μM of dapagliflozin treated hypoxic HK2 cell group showed elevated glucose concentra-
tion of culture medica, compared to non-treated hypoxic HK2 cell group. However, in nor-
moxic condition, there were no significant difference between dapagliflozin treated groups and
non-treated group (Fig 5E).
In mice, IR-injured kidneys showed marked elevation in HIF1 expression. Moreover, dapa-
gliflozin pretreatment significantly elevated the HIF1 expression in IR-injured renal tubular
cells (Fig 6A and 6B). However, albendazole treatment reduced the HIF1 expression (Fig 6A
and 6B). Also, albendazole treatment significantly increased the BUN and serum creatinine lev-
els (Fig 6C), and increased the tissue injury and TUNEL-positive cells in dapagliflozin-treated
IR-injured mice (Fig 6D–6F).
Discussion
This study clearly demonstrated that dapagliflozin, an SGLT2 inhibitor, improves renal func-
tion and reduces apoptotic cell death in IR-injured kidneys in mice. In addition, dapagliflozin
induces HIF1 and reduces the Bax/Bcl2 ratio in ischemic renal tissue and cultured ischemic
tubular cells.
HIF1 plays a beneficial role in cellular adaptation to IR-induced injury [20, 21]. Although
several reports have found no protective effect of HIF1 in liver IR injury [22, 23], many studies
have shown that genetic or pharmacologic activation of HIF1 ameliorates IR injury in various
organs [8–11]. In kidney, IR-injured HIF1α-KO mice showed more severe renal tubulointersti-
tial injury and deteriorated renal function compared with wild-type IR-injured mice [24]. HIF1
preservation via prolyl hydroxylase domain (PHD) inhibition showed a potent renal protective
effect in IR-injured rats [25]. Moreover, HIF1 induction ameliorates apoptosis in IR-injured
kidney via Bax and/or Bcl2 regulation [25, 26]. In our study, dapagliflozin increased HIF1
expression, reduced Bax expression and TUNEL positive cells, and increased Bcl2 expression
in IR-injured kidneys. Moreover, HIF1 inhibition by albendazole ameliorated the dapagliflo-
zin-induced benefits on IR-injured kidneys. These results suggest that the renoprotective
effects of dapagliflozin are associated with the induction of HIF1.
Dapagliflozin is a newly developed diabetes medicine. Because the SGLT2 in the proximal
tubule accounts for the vast majority of glucose reabsorption by the kidney, inhibition of
SGLT2 can decrease glucose levels in the blood. Nakamura et al. reported that high glucose or
advanced glycation end-product (AGE) did not elevate SLGT2 expression in human proximal
tubular cells [27]. However, recent studies have shown that the effects of specific SGLT2 inhibi-
tion in human proximal tubular (HK2) cells exposed to high glucose reduced inflammatory
and fibrotic markers in both polarized and non-polarized settings [15, 28]. It is unclear whether
SGLT2 plays a role in proximal tubular cells under normal glucose conditions. Zapata-Morales
et al. reported that hypoxic conditions decrease SLGT2 expression in porcine proximal tubular
cells [14]. Nakamura et al. reported that insulin and ROS increase the expression of SGLT2 and
glucose uptake in proximal tubular cells [27]. Therefore, SGLT2 may play a role in various
tubular injuries.
Zapata-Morales et al. reported that HIF1 induction by hypoxia or cobalt chloride sup-
pressed the expression of SGLT2 in proximal tubular cells [14]. Similarly, our study showed
that hypoxic insult increased HIF1 expression and decreased SGLT2 expression in HK2 cells. It
is unknown whether SLGT2 regulates HIF1. SGLT2 inhibition by dapagliflozin increased the
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expression of HIF1 in ischemic HK2 cells; however, this study did not address whether overex-
pression of SLGT2 regulates HIF1 expression in HK2 cells.
Although several factors are known to regulate HIF, the mechanism underlying dapagliflo-
zin-induced HIF1 expression in hypoxic or normal HK2 cells is unclear. Phosphorylation of
AMPK and EKR induces HIF1 expression in hypoxic conditions [29, 30]. In addition, PHDs
are inhibited during hypoxia. Decreased PHDs lead to the accumulation of HIF1α subunit,
which dimerize with HIF1β resulting in increased HIF1 levels. Activation of the PI3K/Akt sig-
naling pathway plays a major role in HIFα accumulation during the reperfusion period [31]. In
Fig 6. Effects of dapagliflozin on HIF1 in IR-injured kidneys (S (n = 5), sham; S+Dapa (n = 5), sham+dapagliflozin; IR (n = 7); vehicle-treated
renal IR mice; IR+Dapa (n = 7), dapagliflozin-treated IR mice; IR+Dapa+ABZ (n = 7), albendazole- and dapagliflozin-treated IRmice). (A)
Representative Western blot: dapagliflozin increased HIF1 expression in IR-injured kidneys. Albendazole decreased HIF1 expression in
dapagliflozin-treated IR-injured kidney. (B) Representative Immunohistochemistry of HIF1. Dapagliflozin increase the HIF1 stained area in tubular
area of IR kidney. Original magnification, 200× (C) The effects of dapagliflozin on renal function. Albendazole treatment elevated BUN and serum
creatinine in dapagliflozin-treated IR mice. (D–F) Representative kidney section: albendazole treatment increase tubulointerstitial injury and
TUNEL-positive cells in IR-injured kidneys. *P < 0.05 vs. vehicle-treated sham, **P < 0.05 vs. vehicle-treated IR, #P < 0.05 vs. dapagliflozin-treated
IR. Bar represents mean ± s.d.
doi:10.1371/journal.pone.0158810.g006
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our study, dapagliflozin elevated phosphorylated AMPK and EKR in hypoxic HK2 cells. It is
possible that elevated phosphorylated AMPK and ERK induce HIF1. In addition, dapagliflozin
treatment showed decreased glucose uptake and reduced SGLT2 expression in hypoxic HK2
cells. Decreased glucose uptake in hypoxic cells may induce AMPK and EKR phosphorylation.
Although this study did not address whether SGLT2 regulates HIF1 directly, dapagliflozin-
induced cellular glucose deficiency may induce HIF1. However, in normoxic conditions, dapa-
gliflozin did not affect the glucose consumption in tubular cells. Moreover, dapagliflozin did
not increase the phosphorylation of AMPK and ERK. HIF1 expression increased in dapagliflo-
zin-treated control HK2 cells, suggesting that dapagliflozin regulates HIF1 directly, and not via
low cellular glucose. Layton et at reported that acute SGLT2 inhibition increase 5% oxygen
consumption (calculated by ATP consumption) in renal cortex from baseline non-diabetic kid-
ney [16]. Although it is not evaluated IR injured kidney, it may be possible that SGLT2 inhibi-
tion induced increase of APT consumption, result in HIF-1 generation. Recently, SGLT2
inhibition reduced cardiovascular mortality in type 2 diabetes patients [32]. It could be possible
that SLGT2 inhibitor may favorable effect to damaged heart via HIF1 activation. However, It is
uncertain not only whether long term treatment of dapagliflozin may affect the HIF1 expres-
sion, but also whether dapagliflozin may affect the damaged heart. Although HIF1 activation
reduce various acute organ injury, long term HIF1 activation may induce tissue fibrosis.
This study showed that dapagliflozin attenuates renal IR injury. Elevated HIF1 expression
by dapagliflozin pretreatment may play a major role in the protection of IR-injured renal
tubule cells.
Author Contributions
Conceived and designed the experiments: DEC BJL KWL KRN. Performed the experiments:
YKC HSC JYJ. Analyzed the data: DEC BJL YKC. Contributed reagents/materials/analysis
tools: DEC YKC HSC. Wrote the paper: DEC BJL.
References
1. Veroux M, Corona D, Giuffrida G, Gagliano M, Tallarita T, Giaquinta A, et al. Acute renal failure due to
ureteral obstruction in a kidney transplant recipient with Candida albicans contamination of preserva-
tion fluid. Transpl Infect Dis. 2009; 11(3):266–8. doi: 10.1111/j.1399-3062.2009.00388.x PMID:
19392732.
2. FernandoM, Peake PW, Endre ZH. Biomarkers of calcineurin inhibitor nephrotoxicity in transplantation.
Biomark Med. 2014; 8(10):1247–62. doi: 10.2217/bmm.14.86 PMID: 25525985.
3. Vercauteren SR, Ysebaert DK, Van Rompay AR, De Greef KE, De Broe ME. Acute ischemia/reperfu-
sion injury after isogeneic kidney transplantation is mitigated in a rat model of chronic renal failure. Am
J Transplant. 2003; 3(5):570–80. PMID: 12752313.
4. Choi DE, Jeong JY, Lim BJ, Chung S, Chang YK, Lee SJ, et al. Pretreatment of sildenafil attenuates
ischemia-reperfusion renal injury in rats. American journal of physiology Renal physiology. 2009; 297
(2):F362–70. doi: 10.1152/ajprenal.90609.2008 PMID: 19474186.
5. Versteilen AM, Di Maggio F, Leemreis JR, Groeneveld AB, Musters RJ, Sipkema P. Molecular mecha-
nisms of acute renal failure following ischemia/reperfusion. Int J Artif Organs. 2004; 27(12):1019–29.
PMID: 15645611.
6. Nangaku M, Inagi R, Miyata T, Fujita T. Hypoxia and hypoxia-inducible factor in renal disease. Nephron
Exp Nephrol. 2008; 110(1):e1–7. doi: 10.1159/000148256 PMID: 18667839.
7. Haase VH. Hypoxia-inducible factors in the kidney. American journal of physiology Renal physiology.
2006; 291(2):F271–81. doi: 10.1152/ajprenal.00071.2006 PMID: 16554418; PubMed Central PMCID:
PMCPMC4232221.
8. Baranova O, Miranda LF, Pichiule P, Dragatsis I, Johnson RS, Chavez JC. Neuron-specific inactivation
of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cere-
bral ischemia. J Neurosci. 2007; 27(23):6320–32. doi: 10.1523/JNEUROSCI.0449-07.2007 PMID:
17554006.
Dapagliflozin Attenuates Renal Injury
PLOS ONE | DOI:10.1371/journal.pone.0158810 July 8, 2016 12 / 14
9. Adluri RS, Thirunavukkarasu M, Dunna NR, Zhan L, Oriowo B, Takeda K, et al. Disruption of hypoxia-
inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1-/-) attenuates ex vivo myocardial
ischemia/reperfusion injury through hypoxia-inducible factor-1alpha transcription factor and its target
genes in mice. Antioxid Redox Signal. 2011; 15(7):1789–97. doi: 10.1089/ars.2010.3769 PMID:
21083501; PubMed Central PMCID: PMCPMC3159109.
10. Guo JY, Yang T, Sun XG, Zhou NY, Li FS, Long D, et al. Ischemic postconditioning attenuates liver
warm ischemia-reperfusion injury through Akt-eNOS-NO-HIF pathway. J Biomed Sci. 2011; 18:79. doi:
10.1186/1423-0127-18-79 PMID: 22035453; PubMed Central PMCID: PMCPMC3212808.
11. Weidemann A, Bernhardt WM, Klanke B, Daniel C, Buchholz B, Campean V, et al. HIF activation pro-
tects from acute kidney injury. J Am Soc Nephrol. 2008; 19(3):486–94. doi: 10.1681/ASN.2007040419
PMID: 18256363; PubMed Central PMCID: PMCPMC2391048.
12. Yeh CH, Hsu SP, Yang CC, Chien CT, Wang NP. Hypoxic preconditioning reinforces HIF-alpha-depen-
dent HSP70 signaling to reduce ischemic renal failure-induced renal tubular apoptosis and autophagy.
Life Sci. 2010; 86(3–4):115–23. doi: 10.1016/j.lfs.2009.11.022 PMID: 19962996.
13. Schley G, Klanke B, Schodel J, Kroning S, Turkoglu G, Beyer A, et al. Selective stabilization of HIF-
1alpha in renal tubular cells by 2-oxoglutarate analogues. Am J Pathol. 2012; 181(5):1595–606. doi:
10.1016/j.ajpath.2012.07.010 PMID: 22944601.
14. Zapata-Morales JR, Galicia-Cruz OG, Franco M, Martinez YMF. Hypoxia-inducible factor-1alpha (HIF-
1alpha) protein diminishes sodium glucose transport 1 (SGLT1) and SGLT2 protein expression in renal
epithelial tubular cells (LLC-PK1) under hypoxia. The Journal of biological chemistry. 2014; 289
(1):346–57. doi: 10.1074/jbc.M113.526814 PMID: 24196951; PubMed Central PMCID: PMC3879557.
15. Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, et al. Effects of SGLT2 inhibi-
tion in human kidney proximal tubular cells—renoprotection in diabetic nephropathy? PloS one. 2013;
8(2):e54442. doi: 10.1371/journal.pone.0054442 PMID: 23390498; PubMed Central PMCID:
PMC3563635.
16. Layton AT, Vallon V, Edwards A. Predicted Consequences of Diabetes and SGLT Inhibition on Trans-
port and Oxygen Consumption along a Rat Nephron. American journal of physiology Renal physiology.
2016:ajprenal 00543 2015. doi: 10.1152/ajprenal.00543.2015 PMID: 26764207.
17. O'Neill J, Fasching A, Pihl L, Patinha D, Franzen S, Palm F. Acute SGLT inhibition normalizes O2 ten-
sion in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic
rats. American journal of physiology Renal physiology. 2015; 309(3):F227–34. doi: 10.1152/ajprenal.
00689.2014 PMID: 26041448.
18. Chang YK, Choi DE, Na KR, Lee SJ, Suh KS, Kim SY, et al. Erythropoietin attenuates renal injury in an
experimental model of rat unilateral ureteral obstruction via anti-inflammatory and anti-apoptotic effects.
J Urol. 2009; 181(3):1434–43. doi: 10.1016/j.juro.2008.10.105 PMID: 19157461.
19. Lee KW, Jeong JY, Lim BJ, Chang YK, Lee SJ, Na KR, et al. Sildenafil attenuates renal injury in an
experimental model of rat cisplatin-induced nephrotoxicity. Toxicology. 2009; 257(3):137–43. doi: 10.
1016/j.tox.2008.12.017 PMID: 19152827.
20. Gunaratnam L, Bonventre JV. HIF in kidney disease and development. J Am Soc Nephrol. 2009; 20
(9):1877–87. doi: 10.1681/ASN.2008070804 PMID: 19118148.
21. Haase VH. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int.
2006; 69(8):1302–7. doi: 10.1038/sj.ki.5000221 PMID: 16531988.
22. Cursio R, Miele C, Filippa N, Van Obberghen E, Gugenheim J. Liver HIF-1 alpha induction precedes
apoptosis following normothermic ischemia-reperfusion in rats. Transplant Proc. 2008; 40(6):2042–5.
doi: 10.1016/j.transproceed.2008.05.037 PMID: 18675125.
23. Knudsen AR, Kannerup AS, Dich R, Funch-Jensen P, Gronbaek H, Kruhoffer M, et al. Ischemic pre-
and postconditioning has pronounced effects on gene expression profiles in the rat liver after ischemia/
reperfusion. Am J Physiol Gastrointest Liver Physiol. 2012; 303(4):G482–9. doi: 10.1152/ajpgi.00337.
2011 PMID: 22679003.
24. Hill P, Shukla D, Tran MG, Aragones J, Cook HT, Carmeliet P, et al. Inhibition of hypoxia inducible fac-
tor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol. 2008; 19(1):39–
46. doi: 10.1681/ASN.2006090998 PMID: 18178798; PubMed Central PMCID: PMCPMC2391027.
25. Song H, Han IY, Kim Y, Kim YH, Choi IW, Seo SK, et al. The NADPH oxidase inhibitor DPI can abolish
hypoxia-induced apoptosis of human kidney proximal tubular epithelial cells through Bcl2 up-regulation
via ERK activation without ROS reduction. Life Sci. 2015; 126:69–75. doi: 10.1016/j.lfs.2015.02.004
PMID: 25744050.
26. Yang CC, Lin LC, Wu MS, Chien CT, Lai MK. Repetitive hypoxic preconditioning attenuates renal
ischemia/reperfusion induced oxidative injury via upregulating HIF-1 alpha-dependent bcl-2 signaling.
Transplantation. 2009; 88(11):1251–60. doi: 10.1097/TP.0b013e3181bb4a07 PMID: 19996924.
Dapagliflozin Attenuates Renal Injury
PLOS ONE | DOI:10.1371/journal.pone.0158810 July 8, 2016 13 / 14
27. Nakamura N, Matsui T, Ishibashi Y, Yamagishi S. Insulin stimulates SGLT2-mediated tubular glucose
absorption via oxidative stress generation. Diabetol Metab Syndr. 2015; 7:48. doi: 10.1186/s13098-
015-0044-1 PMID: 26023321; PubMed Central PMCID: PMCPMC4447012.
28. Morrisey K, Steadman R, Williams JD, Phillips AO. Renal proximal tubular cell fibronectin accumulation
in response to glucose is polyol pathway dependent. Kidney Int. 1999; 55(6):2548–72. doi: 10.1046/j.
1523-1755.2002.t01-1-00454.x PMID: 10354307.
29. Lee M, Hwang JT, Lee HJ, Jung SN, Kang I, Chi SG, et al. AMP-activated protein kinase activity is criti-
cal for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic
conditions in DU145 cells. The Journal of biological chemistry. 2003; 278(41):39653–61. doi: 10.1074/
jbc.M306104200 PMID: 12900407.
30. Minet E, Arnould T, Michel G, Roland I, Mottet D, Raes M, et al. ERK activation upon hypoxia: involve-
ment in HIF-1 activation. FEBS Lett. 2000; 468(1):53–8. PMID: 10683440.
31. Conde E, Alegre L, Blanco-Sanchez I, Saenz-Morales D, Aguado-Fraile E, Ponte B, et al. Hypoxia
inducible factor 1-alpha (HIF-1 alpha) is induced during reperfusion after renal ischemia and is critical
for proximal tubule cell survival. PloS one. 2012; 7(3):e33258. doi: 10.1371/journal.pone.0033258
PMID: 22432008; PubMed Central PMCID: PMCPMC3303832.
32. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular
Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117–28. doi: 10.1056/
NEJMoa1504720 PMID: 26378978.
Dapagliflozin Attenuates Renal Injury
PLOS ONE | DOI:10.1371/journal.pone.0158810 July 8, 2016 14 / 14
